Human embryonic stem cell technologies and drug discovery
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Development of new drugs is costly and takes huge resources into consideration. The big pharmaceutical companies are currently facing increasing developmental costs and a lower success‐rate of bringing new compounds to the market. Therefore, it is now of outmost importance that the drug‐hunting companies minimize late attritions due to sub‐optimal pharmacokinetic properties or unexpected toxicity when entering the clinical programs. To achieve this, a strong need to test new candidate drugs in assays of high human relevance in vitro as early as possible has been identified. The traditionally used cell systems are however remarkably limited in this sense, and new improved technologies are of greatest importance. The human embryonic stem cells (hESC) is one of the most powerful cell types known. They have not only the possibility to divide indefinitely; these cells can also differentiate into all mature cell types of the human body. This makes them potentially very valuable for pharmaceutical development, spanning from use as tools in early target studies, DMPK or safety assessment, as screening models to find new chemical entities modulating adult stem cell fate, or as the direct use in cell therapies. This review illustrates the use of hESC in the drug discovery process, today, as well as in a future perspective. This will specifically be exemplified with the most important cell type for pharmaceutical development—the hepatocyte. We discuss how hESC‐derived hepatocyte‐like cells could improve this process, and how these cells should be cultured if optimized functionality and usefulness should be achieved. J. Cell. Physiol. 219: 513–519, 2009. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 1×
“Stirred tanks have been employed for expansion and differentiation of mouse ES cells both as aggregates and on micro carriers (see King and Miller, 2007 for review).”
MethodHewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Hay, D. C., Zhao, D., Fletcher, J., Hewitt, Z. A., McLean, D., Urruticoechea-Uriguen, A., Black, J. R., Elcombe, C., Ross, J. A., Wolf, R., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0718 · Cited by 441 · cited 1×
“Therefore, extensive studies have been performed in order to improve hepatic culture conditions (for review, see Hewitt et al., 2007).”
BackgroundGeneration of Hepatocyte-Like Cells from Human Embryonic Stem Cells
Rambhatla, L., Chiu, C.-P., Kundu, P., Peng, Y., & Carpenter, M. K. (2003) · Cell Transplantation · doi:10.3727/000000003783985179 · Cited by 437
Differentiation of human embryonic stem cells into hepatocytes in 2D and 3D culture systems in vitro
Baharvand, H., Hashemi, S. M., Kazemi Ashtiani, S., & Farrokhi, A. (2006) · The International Journal of Developmental Biology · doi:10.1387/ijdb.052072hb · Cited by 429
Niebruegge, S., Bauwens, C. L., Peerani, R., Thavandiran, N., Masse, S., Sevaptisidis, E., Nanthakumar, K., Woodhouse, K., Husain, M., Kumacheva, E., et al. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22065 · Cited by 222 · cited 2×
“Analyses addressing function have shown that these cells are electrophysiologically active and respond to pharmacological stimuli, suggesting that they have operational ion channels as well as active adrenergic and muscarinic receptor coupling systems (Norstrom et al., 2006).”
BackgroundMethod
Cited by
Faulkner-Jones, A., Fyfe, C., Cornelissen, D.-J., Gardner, J., King, J., Courtney, A., & Shu, W. (2015) · Biofabrication · doi:10.1088/1758-5090/7/4/044102 · Cited by 474
Microfluidic cell culture systems for drug research
Wu, M.-H., Huang, S.-B., & Lee, G.-B. (2010) · Lab on a Chip · doi:10.1039/b921695b · Cited by 432
Process engineering of human pluripotent stem cells for clinical application
Serra, M., Brito, C., Correia, C., & Alves, P. M. (2012) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.03.003 · Cited by 303
Thermoreversible Hyaluronic Acid‐PNIPAAm Hydrogel Systems for 3D Stem Cell Culture
Ekerdt, B. L., Fuentes, C. M., Lei, Y., Adil, M. M., Ramasubramanian, A., Segalman, R. A., & Schaffer, D. V. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800225 · Cited by 117
Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery
Braam, S. R., Passier, R., & Mummery, C. L. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.001 · Cited by 86
Metadata
- Authors
- Jensen, J., Hyllner, J., & Björquist, P.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2009-03-10
- Volume
- 219
- Issue
- 3
- Pages
- 513-519
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W1987739903
- Cited by
- 122
- References
- 7
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human embryonic stem cell technologies and drug discovery. https://app.cochat.ai/papers/10.1002/jcp.21732
- The paper
- Jensen, J., Hyllner, J., & Björquist, P. (2009). Human embryonic stem cell technologies and drug discovery. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.21732
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.